Dendreon transforms the battle against cancer with personalized immunotherapy, developing PROVENGE, the first FDA-approved immunotherapy for metastatic prostate cancer. The company operates manufacturing facilities in California and Georgia, with a commercial organization across the United States and a culture focused on patients, integrity, trust, and innovation.